Delta-8 THC Products Are a Growing Concern for FDA

Delta-8 THC Products Are a Growing Concern for FDA

 

Delta-8 tetrahydrocannabinol (Delta-8 THC), as found in many popular products, is a compound that can be made by chemical conversion of cannabidiol (CBD) extracted from hemp. Delta-8 THC is an isomer of Delta-9 THC and has similar psychoactive and intoxicating effects. Both THC isomers are found at very low levels in “hemp” (as defined in the 2018 Farm Bill). There was very little regulatory focus on Delta-8 THC until an array of new products, including gummies, brownies, and cookies, began popping up on-line and in gas stations, convenience stores and other retail outlets in late 2020.Hit on delta 8 thc legal  to explore more about our services and sites. Hope you ll like our more services.

A September 14, 2021 consumer update from the Food and Drug Administration (FDA), titled “5 Things to Know about Delta-8 Tetrahydrocannabinol – Delta-8 THC, ” was issued in reaction to multiple factors, including an uptick in adverse event reports, finding Delta-8 THC products marketed to children, and contamination concerns from potentially unsafe manufacturing methods. FDA’s public notification covers five things to know about Delta-8 THC products as follows:

Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put public health at risk, including variable Delta-8 THC concentrations, non-standardized formulations, misleading labeling, other cannabinoid and terpene content, and unauthorized claims for therapeutic or medical use.

FDA has received adverse event reports involving 22 patients who experienced vomiting, hallucinations, trouble standing, and/or loss of consciousness following the ingestion of Delta-8 THC products, with 19 such patients having consumed food products containing Delta-8 THC. National poison control centers have reported 661 exposure cases of Delta-8 THC, with 660 occurring between January 1, 2021 and July 31, 2021, and 39% involving mostly unintentional exposures in pediatric patients less than 18 years of age.

Leave a Reply

Your email address will not be published. Required fields are marked *